Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 1, 2000
THE WOODLANDS, Texas, Aug. 1 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) today announced the formalization of a joint research collaboration with Arena Pharmaceuticals (Nasdaq: ...
Jul 28, 2000
SAN DIEGO, July 28 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its initial public offering of 6,000,000 shares of its common stock was priced at $18 per share, above the initial filing range of $15-$17 per share. All of the shares are being sold by Arena. The shares will be offered through an underw...
Jul 28, 2000
NEW YORK, July 28 (Reuters) - The initial public offering market has regained the pizazz that made it famous during its heyday last year -- at least for now.While the technology-rich Nasdaq composite index (^IXIC - news...
Jul 28, 2000
July 28, 2000--Arena Pharmaceuticals, Inc. (Nasdaq:ARNA - news) was admitted to the Nasdaq National Market System following its initial public offering of 6 million shares at $18 per share. The company's stock trades under the ticker symbol ARNA. Company address: 6...
Jul 27, 2000
NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq:ARNA - news) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the...
Jul 25, 2000
WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares.The company, which says it has developed technology that identifies drug candidates more efficiently that traditional techniques,...
Jun 22, 2000
WASHINGTON, June 22 (Reuters) - Arena Pharmaceuticals Inc., which says it has found a new way of finding new drug candidates more efficiently, on Thursday said it will offer five million shares in a projected price range of $15-$17 per share when it goes public.It expects to raise about $73...
Apr 17, 2000
INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening targets, utilizing Arena's proprietary CART™...
Jan 31, 2000
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have entered into a collaboration involving Arena's proprietary CART™ Technology...
Jan 19, 2000
SAN DIEGO, Jan. 19 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, announced today that it was awarded a one-year, $106,000 Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The Company will ...
Sep 15, 1999
SAN DIEGO, Sept. 15 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced a collaboration involving the application of Arena's constitutive activation technology to three Neurocrine orphan G protein-coupled recepto...
Apr 17, 1999
SAN DIEGO, May 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, announced the successful completion of a Phase I clinical investigation of the safety and pharmacokinetics of T-82 in healthy, elderly volunteers. This was a first-in-man study ...
Feb 22, 1999
SAN DIEGO, Feb. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, has announced the successful completion of a private offering through the sale of its Series D Preferred Stock. Arena had intended to raise $10 Million through this offer...
= add release to Briefcase